Polyzos SA, Mantzoros CS. Nonalcoholic fatty future disease. Metab Clin Exp. 2016;65(8):1007–16.
Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005–23.
Hazlehurst JM, Woods C, Marjot T, Cobbold JF, Tomlinson JW. Non-alcoholic fatty liver disease and diabetes. Metabolism. 2016;65(8):1096–108.
Sangouni AA, Ghavamzadeh S, Jamalzehi A. A narrative review on effects of vitamin D on main risk factors and severity of non-alcoholic fatty liver disease. Diabetes Metab Syndr Clin Res Rev. 2019;13(3):2260–5.
Laville M, Nazare JA. Diabetes, insulin resistance and sugars. Obes Rev. 2009;10(Suppl 1):24–33.
Tkáč I. Metabolic syndrome in relationship to type 2 diabetes and atherosclerosis. Diabetes Res Clin Pract. 2005;68(Suppl 1):S2–9.
Araújo AR, Rosso N, Bedogni G, Tiribelli C, Bellentani S. Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: what we need in the future. Liver Int. 2018;38(Suppl 1):47–51.
Abdul M, Khan B, Hashim MJ, King JK, Govender RD, Mustafa H, et al. Epidemiology of type 2 Diabetes – global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020;10:107–11.
Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013;5(5):1544–60.
Koca TT, Tugan CB, Seyithanoglu M, Kocyigit BF. The clinical importance of the plasma atherogenic index, other lipid indexes, and urinary sodium and potassium excretion in patients with stroke. Eurasian J Med. 2019;51(2):171–5.
Fernández-Macías JC, Ochoa-Martínez AC, Varela-Silva JA, Pérez-Maldonado IN. Atherogenic index of plasma: novel predictive biomarker for cardiovascular illnesses. Arch Med Res. 2019;50(5):285–94.
Sujatha R, Kavitha S. Atherogenic indices in stroke patients: a retrospective study. Iran J Neurol. 2017;16(2):78–82.
Sangouni AA, Sasanfar B, Ghadiri-Anari A, Hosseinzadeh M. Effect of L-carnitine supplementation on liver fat content and cardiometabolic indices in overweight/obese women with polycystic ovary syndrome: a randomized controlled trial. Clin Nutr ESPEN. https://doi.org/10.1016/j.clnesp.2021.08.005.
Izadi A, Shirazi S, Taghizadeh S, Gargari BP. Independent and additive effects of coenzyme Q10 and vitamin E on Cardiometabolic outcomes and visceral adiposity in women with polycystic ovary syndrome. Arch Med Res. 2019;50(2):1–10.
Lombardo YB, Chicco AG. Effects of dietary polyunsaturated n-3 fatty acids on dyslipidemia and insulin resistance in rodents and humans. A review. J Nutr Biochem. 2006;17(1):1–13.
Kromhout D, Yasuda S, Geleijnse JM, Shimokawa H. Fish oil and omega-3 fatty acids in cardiovascular disease: do they really work? Eur Heart J. 2012;33(4):436–43.
Albracht-Schulte K, Kalupahana NS, Ramalingam L, Wang S, Rahman SM, Robert-McComb J, et al. Omega-3 fatty acids in obesity and metabolic syndrome: a mechanistic update. J Nutr Biochem. 2017;2018(58):1–16.
Alwayn IPJ, Andersson C, Zauscher B, Gura K, Nosé V, Puder M. Omega-3 fatty acids improve hepatic steatosis in a murine model: potential implications for the marginal steatotic liver donor. Transplantation. 2005;79(5):606–8.
Alwayn IPJ, Gura K, Nosé V, Zausche B, Javid P, Garza J, et al. Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease. Pediatr Res. 2005;57(3):445–52.
Di Minno MND, Russolillo A, Lupoli R, Ambrosino P, Di Minno A, Tarantino G. Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. World J Gastroenterol. 2012;18(41):5839–47.
Davidson MH. Mechanisms for the Hypotriglyceridemic effect of marine Omega-3 fatty acids. Am J Cardiol. 2006;98(4 SUPPL.1):27–33.
Capanni M, Calella F, Biagini MR, Genise S, Raimondi L, Bedogni G, et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther. 2006;23(8):1143–51.
Crestani DM, Bonin ÉFR, Barbieri RA, Zagatto AM, Higino WP, Milioni F. Chronic supplementation of omega-3 can improve body composition and maximal strength, but does not change the resistance to neuromuscular fatigue. Sport Sci Health. 2017;13(2):259–65.
Dasarathy S, Dasarathy J, Khiyami A, Yerian L, Hawkins C, Sargent R, et al. Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol. 2015;49(2):137–44.
Orang Z, Mohsenpour MA, Mozaffari-Khosravi H. Effect of Omega-3 fatty acid supplementation on inflammatory markers and insulin resistance indices in patient with type 2 diabetes and nonalcoholic fatty liver: a randomized double-blind clinical trial. Obes Med. 2020;19(July):100278.
Orang Z, Mozaffari-Khosravi H, Sivandzadeh G, Pantovic A. The effect of omega-3 supplementation on glycemic indices and lipid profile in type 2 diabetic patients with non-alcoholic fatty liver disease: a double-blind, randomized, clinical trial. Med J Nutrition Metab. 2019;12(2):187–96.
Diabetes AA. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;36(Suppl 1):S67–74.
Saghaei M. Random allocation software for parallel group randomized trials. BMC Med Res Methodol. 2004;4:26.
Samimi M, Jamilian M, Asemi Z, Esmaillzadeh A. Effects of omega-3 fatty acid supplementation on insulin metabolism and lipid profiles in gestational diabetes: randomized, double-blind, placebo-controlled trial. Clin Nutr. 2015;34(3):388–93.
Pehrsson PR, Haytowitz DB, Holden JM, Perry CR, Beckler DG. USDA’s national food and nutrient analysis program: food sampling. J Food Compos Anal. 2000;13(4):379–89.
Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath SJ, et al. Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc. 2000;32(9 SUPPL):S498–504.
Dobiášová M, Frohlich J, Šedová M, Cheung MC, Brown BG. Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography. J Lipid Res. 2011;52(3):566–71.
Singh M, Pathak MS, Paul A. A study on atherogenic indices of pregnancy induced hypertension patients as compared to normal pregnant women. J Clin Diagn Res. 2015;9(7):BC05–8.
Zibaeenezhad MJ, Ghavipisheh M, Attar A, Aslani A. Comparison of the effect of omega-3 supplements and fresh fish on lipid profile: a randomized, open-labeled trial. Nutr Diabetes. 2017;7(12):1–8.
Mozaffarian D. Fish, mercury, selenium and cardiovascular risk: current evidence and unanswered questions. Int J Environ Res Public Health. 2009;6(6):1894–916.
Brown K, Arthur J. Selenium, selenoproteins and human health: a review. Public Health Nutr. 2001;4(2b):593–9.
McEwen BJ, Morel-Kopp MC, Tofler GH, Ward CM. The effect of omega-3 polyunsaturated fatty acids on fibrin and thrombin generation in healthy subjects and subjects with cardiovascular disease. Semin Thromb Hemost. 2015;41(3):315–22.
DeFilippis AP, Blaha MJ, Jacobson TA. Omega-3 fatty acids for cardiovascular disease prevention. Curr Treat Options Cardiovasc Med. 2010;12(4):365–80.
Calder PC. Omega-3 fatty acids and inflammatory processes. Nutrients. 2010;2(3):355–74.
Pachikian BD, Essaghir A, Demoulin JB, Neyrinck AM, Catry E, de Backer FC, et al. Hepatic n-3 polyunsaturated fatty acid depletion promotes steatosis and insulin resistance in mice: genomic analysis of cellular targets. PLoS One. 2011;6(8):e23365.
Scorletti E, Bhatia L, Mccormick KG, Clough GF, Nash K, Hodson L, et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the WELCOME* study. Hepatology. 2014;60(4):1211–21.
Zhu FS, Liu S, Chen XM, Huang ZG, Zhang DW. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol. 2008;14(41):6395–400.
He XX, Wu XL, Chen RP, Chen C, Liu XG, Wu BJ, et al. Effectiveness of omega-3 polyunsaturated fatty acids in non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials. PLoS One. 2016;11(10):1–22.
Kim HJ, Takahashi M, Ezaki O. Fish oil feeding decreases mature sterol regulatory element-binding protein 1 (SREBP-1) by down-regulation of SREBP-1c mRNA in mouse liver. A possible mechanism for down-regulation of lipogenic enzyme mRNAs. J Biol Chem. 1999;274(36):25892–8.
Khan S, Minihane AM, Talmud PJ, Wright JW, Murphy MC, Williams CM, et al. Dietary long-chain n-3 PUFAs increase LPL gene expression in adipose tissue of subjects with an atherogenic lipoprotein phenotype. J Lipid Res. 2002;43(6):979–85.
Harris WS, Bulchandani D. Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol. 2006;17(4):387–93.
Sangouni AA, Orang Z, Mozaffari-Khosravi H. Effect of omega-3 supplementation on fatty liver and visceral adiposity indices in diabetic patients with non-alcoholic fatty liver disease: a randomized controlled trial. Clin Nutr ESPEN. 2021;44:130–5.
Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011;54(3):1082–90.
Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing Steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(6):1717–30.
Saleh HA, Abu-Rashed AH. Liver biopsy remains the gold standard for evaluation of chronic hepatitis and fibrosis. J Gastrointestin Liver Dis. 2007;16(4):425–6.